Login to Your Account



Deals And M&A NEWS
$15M NOW; $225M POTENTIAL
Angling to strengthen its position in Hunter syndrome by way of a method past the blood-brain barrier, Shire plc – already an investor in Armagen Technologies Inc. – paid $15 million up front and added an equity investment, sweetening the deal to develop the enzyme replacement therapy AGT-182 for somatic as well as CNS effects of Hunter syndrome.

SHANGHAI – HD Biosciences Co. Ltd. has signed an agreement to co-develop drugs with two research centers at Marshall University. The deal was struck after three years of informal collaboration between both sides, and with an eye to entering the clinic in the next two years. The focus of the alliance is to provide innovative medicines for unmet medical needs, particularly cancer and kidney fibrosis, in both China and the U.S.

LONDON – The deals go on for Immunocore Ltd., which has signed Eli Lilly and Co. as the fourth partner in little over a year for its Immtac T-cell receptor technology.
More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: